Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Ovarian Cancer
Interventions
DRUG

Hycamptin

1.75mg/m2 IV on day 1 every week for 3 weeks in cycles of 4 weeks Number of cycles: until progression

DRUG

Gemcitabine

"Gemcitabine at starting dose of 700 mg/m 2 with increments of 100 mg/m2 IV on day 1 every week for 3 weeks in cycles of four weeks.~Number of cycles: until progression"

Trial Locations (6)

71110

University Hospital of Crete, Heraklion

Unknown

University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupoli

"IASO General Hospital of Athnes, Dep of Medical Oncology", Athens

"Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine", Athens

State General Hospital of Larissa, Dep of Medical Oncology, Larissa

"Theagenion Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology", Thessaloniki

All Listed Sponsors
collaborator

University Hospital of Crete

OTHER

lead

Hellenic Oncology Research Group

OTHER